How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,400 results for

Six Item Cognitive Impairment Test

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Alcohol Related Impairment and Reinforcement: Pre to Post Roux en Y Gastric Bypass Surgery

bariatric surgery (RYGB) patients who consume alcohol. In this study the investigators propose to investigate RYGB patients with a prospective, longitudinal design. Investigators will examine driving impairment before and after surgery as well as study cognitive changes and reinforcement changes that may occur in RYGB patients while consuming alcohol. Finally, investigators aim to better characterize the changes that occur in the pharmacokinetics of alcohol following bariatric surgery and examine key (...) variables which may play a role in the development in alcohol use disorders. Condition or disease Intervention/treatment Phase Bariatric Surgery Candidate Other: Alcohol Not Applicable Detailed Description: The three major objectives of this NIH sponsored application are: 1) to characterize the severity of cognitive impairment and driving performance changes following alcohol consumption in a group of patients who have undergone Roux-en-Y Gastric Bypass (RYGB) bariatric surgery and 2) to investigate

2015 Clinical Trials

142. Estrogen Receptors Beta (ER-B) as Therapeutic Targets for the Improvement of Cognitive Performance in Fragile-X (TESXF)

of phosphatidylinositol 3-kinase (PI3K)and mammalian target of rapamycin (mTOR) and extracellular signal-regulated kinase (ERK1/2). This study targets the synaptic plasticity alterations that underlie the learning and memory impairment but also the computational disability in FXS. The hypothesis is that EGCG can act by favoring the physiological processes involved in cognition. Condition or disease Intervention/treatment Phase Fragile X Syndrome Dietary Supplement: EGCG Dietary Supplement: Placebo Other: cognitive (...) of a list of 12 items, which have to be verbally recalled by the examinee during 3 trials of free and cued recall. The test start with a learning phase where the examinee is required to learn the list of 12 items using 12 images. Four pictures are presented at a time, one in each quadrant of a card. First, the examinee have to name each of the four pictures in the card, and secondly assign each picture according to a verbal category-cue given by the examiner. Changes in language (Boston Naming Test

2013 Clinical Trials

143. A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia

Test Part A; Brief Assessment in Cognition in Schizophrenia Symbol Coding; Hopkins Verbal Learning Test-Revised; Wechsler Memory Scale-III Spatial Span; Letter Number Sequencing; Neuropsychological Assessment Battery Mazes; Brief Visuospatial Memory Test-Revised; Category Fluency Animal Naming; Mayer-Salovey-Caruso Emotional Intelligence Test Managing Emotions; and Continuous Performance Test-Identical Pairs. For each test, a score is derived based on the raw item values. Each of the individual (...) : placebo capsules Outcome Measures Go to Primary Outcome Measures : Visual Memory [ Time Frame: Baseline, 8 weeks, and 16 weeks ] To determine the efficacy of adjunctive valacyclovir, in comparison to placebo, to improve visual memory (Brief Visuospatial Memory Test) in individuals who are HSV-1 positive and early in the course of schizophrenia. The Brief Visuospatial Memory Test is a subscale of the MATRICS Consensus Cognitive Battery (MCCB) and was used to assess visual memory. The BVMT consists

2013 Clinical Trials

144. Factor structure of the MATRICS Consensus Cognitive Battery (MCCB) in schizophrenia. Full Text available with Trip Pro

of social skills.These analyses suggest that the six MCCB "domains" as constructed can be collapsed into fewer domains composed of multiple item scores; they also support the notion that impaired processing speed is a fundamental cognitive deficit in schizophrenia and that MCCB performance is related to functional capacity. Cognition and functional capacity measures require more research to determine if they differ.Published by Elsevier B.V. (...) and determine whether its cognitive domains are separable.183 outpatients with schizophrenia or schizoaffective disorder completed a comprehensive test battery. Confirmatory factor analysis was used to test the factor structure of the MCCB; hierarchical regression then examined the relative contribution of individual cognitive variables to predict the MCCB factor scores. Finally, the relationships between the resulting factors and two performance-based measures of functional capacity were explored.A three

2013 Schizophrenia Research

145. Internet-delivered Cognitive Behavior Therapy for Adolescents With Functional Gastrointestinal Disorders: a Pilot Study

Internet-delivered Cognitive Behavior Therapy for Adolescents With Functional Gastrointestinal Disorders: a Pilot Study Internet-delivered Cognitive Behavior Therapy for Adolescents With Functional Gastrointestinal Disorders: a Pilot Study - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Internet-delivered Cognitive Behavior Therapy for Adolescents With Functional Gastrointestinal Disorders: a Pilot Study The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02033161 Recruitment Status : Completed First

2013 Clinical Trials

146. Cognitive Rehabilitation Versus Psychoeducation in Psychosocial Functioning of Borderline Personality Disorder

is a 24-item scale that measures the level of psychosocial functioning of patients in daily life situations. It assesses six functional domains: autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal relationships, and leisure time. Higher scores indicate higher functional impairment. This instrument has shown good psychometric properties and sensitivity to change. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate (...) Cognitive Rehabilitation Versus Psychoeducation in Psychosocial Functioning of Borderline Personality Disorder Cognitive Rehabilitation Versus Psychoeducation in Psychosocial Functioning of Borderline Personality Disorder - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2013 Clinical Trials

147. Five short screening tests in the detection of prevalent delirium: diagnostic accuracy and performance in different neurocognitive subgroups. (Abstract)

Five short screening tests in the detection of prevalent delirium: diagnostic accuracy and performance in different neurocognitive subgroups. Delirium is prevalent and serious, yet remains under-recognised. Systematic screening could improve detection; however, consensus is lacking as to the best approach. Our aim was to assess the diagnostic accuracy of five simple cognitive tests in delirium screening: six-item cognitive impairment test (6-CIT), clock-drawing test, spatial span forwards (...) delirium), Wilks' Lambda = 0.748, p < 0.001.The 6-CIT measures attention, temporal orientation and short-term memory and shows promise as a delirium screening test. This study suggests that it may also have potential in distinguishing the cognitive impairment of delirium from that of dementia in older patients. Copyright © 2016 John Wiley & Sons, Ltd.Copyright © 2016 John Wiley & Sons, Ltd.

2016 International Journal of Geriatric Psychiatry

148. Development and Testing of a Behavioral Activation Mobile Therapy for Elevated Depressive Systems

of nicotine dependence related to cigarette smoking. It contains six items that evaluate the quantity of cigarette consumption, the compulsion to use, and dependence. Timeline Followback Method Assessment [ Time Frame: Once a week for 8 weeks ] The Timeline Followback (TLFB) is a method that can be used as a clinical and research tool to obtain a variety of quantitative estimates of marijuana, cigarette, and other drug use. Contemplation Ladder [ Time Frame: Once a week for 8 weeks ] A measure (...) Development and Testing of a Behavioral Activation Mobile Therapy for Elevated Depressive Systems Development and Testing of a Behavioral Activation Mobile Therapy for Elevated Depressive Systems - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove

2015 Clinical Trials

149. Testing a Multilevel Preventive Intervention in Youth Courts

, and provider and participant feedback to determine their impact on program efficacy) and quantitative (survey assessments at pretest, post-test, and six-month follow-up) methods to estimate the effect size of the adapted and combined program. By intervening with both youth court participants and youth court staff, the proposed multilevel intervention can have a broad impact on risk and protective factors at multiple levels of influence. The ultimate goal of this research is to promote the use (...) practice through homework assignments, and didactic teaching methods. Other Name: LST Outcome Measures Go to Primary Outcome Measures : Substance Use Behavior, Intentions, Attitudes and Perceived Norms at Baseline [ Time Frame: Pre-test (prior to participating in the first session of the intervention) ] Substance Use Behavior and Intentions: For 13 substance-related items (e.g., alcohol, tobacco, cocaine, methamphetamines, steroids), participants will be asked to indicate frequency of use. Drug

2015 Clinical Trials

150. Combining Exercise and Cognitive Training to Improve Everyday Function

contraindications to exercise or evidence of dementia or cognitive impairment. Individuals will be randomly assigned to one of four groups for six months: Aerobic Exercise and Health Education, Home Exercise and Cognitive Training, Aerobic Exercise and Cognitive Training, and Home Exercise and Health Education. Participants will undergo measurements of cognitive function, physical performance, and complete questionaires about daily activities, physical activity, and quality of life at baseline (pre-intervention (...) weekly metabolic work (KCals). Uniform Data Set (UDS) [ Time Frame: Baseline, Month 12 ] A standardized interview to ascertain and assess demographic information, health status, cognitive status, medications, and functional status. The interview is conducted with the research participant and a collateral source historian. Geriatric Depression Scale [ Time Frame: Baseline, Month 12 ] A 15-item questionnaire to assess for symptoms of depression. Late Life Function & Disability Index (LLFDI) [ Time

2012 Clinical Trials

151. Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

are also taking stable antipsychotic therapy. Condition or disease Intervention/treatment Phase Schizophrenia Impaired Cognition Drug: EVP-6124 Drug: Placebo Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 767 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: A Randomized (...) General health status acceptable for participation in a 26-week clinical study Fertile, sexually active subjects (men and women) must use an effective method of contraception during the study Fluency (oral and written) in the language in which the standardized tests will be administered The ability to refrain from using any tobacco or other nicotine-containing products for at least 30 minutes before any cognitive testing Exclusion Criteria: Hospitalization within 12 weeks before screening or during

2012 Clinical Trials

152. Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

are also taking stable antipsychotic therapy. Condition or disease Intervention/treatment Phase Schizophrenia Impaired Cognition Drug: EVP-6124 Drug: Placebo Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 753 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: A Randomized (...) General health status acceptable for participation in a 26-week clinical study Fertile, sexually active subjects (men and women) must use an effective method of contraception during the study Fluency (oral and written) in the language in which the standardized tests will be administered The ability to refrain from using any tobacco or other nicotine-containing products for at least 30 minutes before any cognitive testing Exclusion Criteria: Hospitalization within 12 weeks before screening or during

2012 Clinical Trials

153. Depression and Cognitive Impairment in Older Adult Emergency Department Patients: Changes over 2 Weeks. Full Text available with Trip Pro

(Six-Item Screener) was performed. Changes were evaluated through paired comparisons.At 2-week follow-up, for depression, 27 of 97 (28%) with baseline positive tests remained positive, and 22 of 706 (3%) with baseline negative tests were positive. At 2-week follow-up, for cognitive impairment, five of 43 (12%) with baseline positive tests remained positive, and 11 of 765 (1%) with baseline negative tests were positive.Significant variability exists for depression and cognitive impairment testing (...) Depression and Cognitive Impairment in Older Adult Emergency Department Patients: Changes over 2 Weeks. To evaluate older adult emergency department (ED) patients for depression and cognitive impairment and to re-evaluate those findings 2 weeks later.Prospective cohort study.ED.One thousand two hundred six older community-dwelling ED patients consented to participate; 811 (67%) completed the 2-week follow-up.Screening for depression (9-item Patient Health Questionnaire) and cognitive impairment

2011 Journal of the American Geriatrics Society

154. Anosognosia for memory deficit in amnestic mild cognitive impairment and Alzheimer's disease. (Abstract)

Anosognosia for memory deficit in amnestic mild cognitive impairment and Alzheimer's disease. to investigate patterns of anosognosia for memory deficit in subjects with amnestic mild cognitive impairment (MCI) and Alzheimer's disease (AD).the study involved twenty-five subjects with MCI, 15 with mild AD and 21 normal controls (NC). Subjective rating of memory functioning was assessed with a six-items questionnaire that was administered before and after memory testing; an informant version from (...) memory testing. At the OJ task, MCI and AD consistently overestimated their memory performances as compared with NC. The SRD and OJ measures were not correlated with some patients being impaired on only one measure. Only the OJ measure was significantly related to executive functioning.AD and MCI subjects show unawareness for memory deficit and significant memory-monitoring disorder. This confirms that anosognosia is an important symptom of MCI. Similarities of patterns of impaired awareness between

2011 International Journal of Geriatric Psychiatry

155. How do the phq-2, the phq-9 perform in aging services clients with cognitive impairment? Full Text available with Trip Pro

How do the phq-2, the phq-9 perform in aging services clients with cognitive impairment? To examine the performance of the Patient Health Questionnaire-2 (PHQ-2) and the PHQ-9 in detecting current major depressive episode (MDE) in aging services care management clients who screen positive for cognitive impairment (CI).Cross-sectional observational study of 236 care management clients ages ≥60 years recruited from an Upstate NY aging services agency. The test characteristics of the PHQ-2 and PHQ (...) -9 to screen for depression were calculated using the Structured Clinical Interview for DSM-IV (SCID) to identify MDE (gold standard). CI was identified with the Six-Item Screen (SIS).Participants had a mean age of 77 years, 68% female, 16% non-white, and 26% had less than a high school education. 16% of participants had CI identified by ≥2 errors on SIS. Of these, 41% had positive PHQ-2 (scores ≥3), 43% had positive PHQ-9 (scores ≥10), while 24% met criteria for MDE. In the sample with CI

2011 International Journal of Geriatric Psychiatry

156. Feasibility Testing and Evaluation of an Online Toolkit for Male Spouses of Women With Breast Cancer

] Caregiver quality of life is measured by the Caregiver Quality of Life-Cancer (CQOL-C) scale. This scale was developed specifically for family caregivers of persons with cancer. It consists of 35 items using a five-point Likert-type scale. It has four sub-scales: burden (physical and emotional), disruptiveness, positive adaptation and financial concerns. Higher scores reflect higher quality of life. It can be completed in 10 minutes and is considered easy to use. Test-retest reliability was found (...) and older (Adult, Older Adult) Sexes Eligible for Study: Male Accepts Healthy Volunteers: No Criteria Inclusion Criteria: male 18 years of age or older living with a spouse who has breast cancer (Stage 1, 2, or 3) English speaking. Exclusion Criteria: persons who are non-autonomous adults cognitively impaired as determined by the Registered Nurse (RN) researcher unable to participate, in the opinion of the RN researcher non-English speaking does not have a spouse who is diagnosed with having breast

2014 Clinical Trials

157. Combination Treatment Study for Memory Impairment and Depression

six trials (total immediate recall) was obtained. Selective Reminding Test (SRT) Delayed Recall [ Time Frame: Week 16 ] The 12-item, 6-trial SRT is a memory measure used to assess verbal list learning and memory. The total number of words learned over six trials (total immediate recall) and delayed recall (after a 15-minute delay) was obtained. Secondary Outcome Measures : Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog) [ Time Frame: Week 16 ] The modified ADAS-Cog is a cognitive (...) : Of either sex, age 55-95 years old with minimum 8 years of education who meet criteria for both depression and cognitive impairment as described below. Study Criteria for "depression": i. Patients who meet DSM-IV symptom criteria for Major Depression or Dysthymia for a minimum of 6 months (2 year duration DSM-IV TR criterion not required for dysthymic disorder in this study). ii. 24-item HAM-D ≥14. Study Criteria for "cognitive impairment": i. Subjective memory or other cognitive complaints. ii. Score

2012 Clinical Trials

158. Testing the Efficacy of Self-Generation Treatment Protocol

treatment self-generation strategy treatment, embedded within practice of various activities Behavioral: Self-generation treatment self-generation treatment is a cognitive rehabilitation strategy aimed to improve memory. The self-generation strategy treatment, embedded within practice of various activities will consists of six individualized intervention sessions administered over 2-3 weeks Placebo Comparator: memory training Treatment consists on traditional memory training Outcome Measures Go (...) Testing the Efficacy of Self-Generation Treatment Protocol Testing the Efficacy of Self-Generation Treatment Protocol - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Testing the Efficacy of Self-Generation

2013 Clinical Trials

159. Cognitive-Behavioral Therapy and Supportive Psychotherapy for Body Dysmorphic Disorder

(in the patient's and clinician's opinion) and the primary reason for seeking treatment Score of 24 or higher on the BDD-Yale-Brown Obsessive Compulsive Scale Exclusion Criteria: Current clinically significant suicidality and/or score on the BDI-II suicide item (#9) > 1 Any clinical features requiring a higher level of care Mental retardation or borderline intellectual functioning (estimated IQ < 80 on the Wechsler Abbreviated Scale of Intelligence) or dementia, brain damage, or other cognitive impairment (...) chronic, and common disorder consisting of distressing or impairing preoccupation with perceived defects in one's physical appearance. Individuals with BDD have very poor psychosocial functioning and high rates of hospitalization and suicidality. Because BDD differs in important ways from other disorders, psychotherapies for other disorders are not adequate for BDD. Despite BDD's severity, there is no adequately tested psychosocial treatment (psychotherapy) of any type for this disorder. This study

2011 Clinical Trials

160. The Effect of Rasagiline on Cognition in Parkinson's Disease

: Placebo Participants in this group will receive 1 mg of placebo daily for the six month duration of the study. Drug: Placebo 1 mg daily Outcome Measures Go to Primary Outcome Measures : Rey Auditory Verbal Learning Test [ Time Frame: Change in score from day 1 of study enrollment and score after 6 months of treatment ] This is a 15 item supraspan verbal memory test. This measure assesses immediate memory span, new learning, susceptibility to interference, retention, and recognition memory. Secondary (...) . Frakey, Brown University Study Details Study Description Go to Brief Summary: While Parkinson's disease has historically been defined in terms of its motor symptomatology, studies have shown that non-motor deficits form an important part of the syndrome. Cognitive deficits can occur even in the early stages of Parkinson's disease. These deficits are often subtle and do not rise to the level of impairment necessary for a diagnosis of dementia; however these deficits are discernable

2011 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>